WaveMan
WaveMan · Company
STIM · Neuronetics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

STIM Neuronetics (STIM) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001227636
Quote by TradingView
Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
45
13F, latest reported quarter

What the filings say about STIM

Insiders, 180 days
+$860.0K net bought
1 buyer
Planned sales (Form 144), 90 days
$852.2K
2 notices

Neuronetics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Neuronetics, Inc. insiders bought a net $860.0K of stock across 173 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-29.

Insider
Filed
Shares
Value
Since filing
Chernett Jorey
BUY
2026-08-17 SECtraded 2026-08-14
14,000
$44.2K
-30.5%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Jul 14, 2026.
  • +3.7% median (+21.2% mean) 90-day return after 13 previous buys.
  • The trade is 0.1% of the 10,602,988 shares held after it.
  • No other insider bought within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Chernett Jorey bought about $44.2K of STIM on Aug 14, 2026; 45 funds added in the latest 13F quarter.
Chernett Jorey
BUY
2026-07-15 SECtraded 2026-07-14
35,000
$62.3K
+23.0%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on May 19, 2026.
  • +1.1% median (+21.3% mean) 90-day return after 12 previous buys.
  • The trade is 0.3% of the 10,588,988 shares held after it.
  • No other insider bought within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Chernett Jorey bought about $62.3K of STIM on Jul 14, 2026; 45 funds added in the latest 13F quarter.
Chernett Jorey
BUY
2026-05-20 SECtraded 2026-05-19
100,000
$117.0K
+84.0%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on May 12, 2026.
  • -1.6% median (+7.1% mean) 90-day return after 11 previous buys.
  • The trade is 0.9% of the 10,553,988 shares held after it.
  • No other insider bought within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Chernett Jorey bought about $117.0K of STIM on May 19, 2026; 45 funds added in the latest 13F quarter.
Chernett Jorey
BUY
2026-05-13 SECtraded 2026-05-12
475,000
$636.5K
+68.5%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Apr 21, 2026.
  • -3.4% median (+0.7% mean) 90-day return after 10 previous buys.
  • The trade is 4.5% of the 10,453,988 shares held after it.
  • No other insider bought within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Chernett Jorey bought about $636.5K of STIM on May 12, 2026; 45 funds added in the latest 13F quarter.
Chernett Jorey
BUY
2026-04-22 SECtraded 2026-04-21
100,000
$151.0K
+29.6%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Apr 20, 2026.
  • -5.3% median (-3.1% mean) 90-day return after 9 previous buys.
  • The trade is 1.0% of the 9,978,988 shares held after it.
  • No other insider bought within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Chernett Jorey bought about $151.0K of STIM on Apr 21, 2026; 45 funds added in the latest 13F quarter.
173 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 168 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$860.0K over 180 days
+$44.2K over 90 days · +$860.0K of it by a 10%+ holder
more than 91% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
45 funds bought in last quarter
below 60% of Medical Devices
Revenue
+99.2% year over year
more than 92% of Medical Devices
Margin
-26.1% net margin
below 56% of Medical Devices
Buybacks
no share repurchases reported
Short interest
19.4% of the float short (float per yahoo 2026-10-27) · 9.4 days to cover · settled 2026-10-15
more than 86% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch STIM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-29.8%12M
-62%-40%-17%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-03-18 · Chernett Jorey bought $820.0K2026-03-27 · Chernett Jorey bought $675.0K2026-05-12 · Chernett Jorey bought $636.5K2026-03-17 · Chernett Jorey bought $616.0K2026-03-19 · Chernett Jorey bought $598.5K2026-03-30 · Chernett Jorey bought $481.8K2026-03-20 · Chernett Jorey bought $239.0K2026-03-25 · Chernett Jorey bought $175.0K2026-04-20 · Chernett Jorey bought $158.0K2026-04-21 · Chernett Jorey bought $151.0K2026-05-19 · Chernett Jorey bought $117.0K2026-02-10 · Sullivan Keith J sold $63.5K2026-07-14 · Chernett Jorey bought $62.3K2026-03-19 · Sullivan Keith J sold $62.0K2026-02-12 · Sullivan Keith J sold $55.8K2026-08-14 · Chernett Jorey bought $44.2K2026-03-26 · Chernett Jorey bought $36.0K2026-02-12 · MACAN WILLIAM ANDREW sold $23.3K2026-03-19 · Pfanstiel Steven sold $22.0K2026-03-19 · MACAN WILLIAM ANDREW sold $21.4K2026-03-19 · Pfanstiel Steven sold $11.5K2026-02-26 · Sullivan Keith J sold $11.4K2026-02-10 · MACAN WILLIAM ANDREW sold $5.4K2026-02-26 · MACAN WILLIAM ANDREW sold $4.6K2026-03-04 · MACAN WILLIAM ANDREW sold $8162026-03-31 · Chernett Jorey filed a 5%+ stake (14.12%)2026-08-19 · MACAN WILLIAM ANDREW filed to sell $463.9K2026-08-18 · MACAN WILLIAM ANDREW filed to sell $388.3K
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns STIM: institutional holders (13F)

13F holdings, latest reported quarter
Madryn Asset Management, LP
18,540,488 sh
$24.1M
UBS Group AG
2,279,099 sh
$3.0M
WEXFORD CAPITAL LP
2,002,625 sh
$2.6M
FourWorld Capital Management LLC
1,744,142 sh
$2.3M
Lane Generational LLC
1,633,372 sh
$2.1M

Congress trades in STIM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Chernett Jorey
Activist 13D · 2026-03-31
14.12%

STIM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MACAN WILLIAM ANDREW
Filed 2026-08-19
$463.9K
MACAN WILLIAM ANDREW
Filed 2026-08-18
$388.3K

STIM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$965.6K position · as of 2026-06-30
2.2%
Invesco NASDAQ Future Gen 200 ETF
$88.3K position · as of 2026-05-31
0.5%
Ultra-Small Company Market Fund
$123.8K position · as of 2026-06-30
0.1%
Gabelli Global Mini Mites Fund
$10.4K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$121.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$8.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $860.0K bought by insiders over 180 days, 45 funds added last quarter, $852.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

STIM financials

Revenue growth
+99.2%
XBRL, annual
Net margin
-26.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$155.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-19.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$11.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
4.09x
long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.14x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end)
Return on equity
-135.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-22.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-21.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$220.6M
market value at close 2026-10-27 on 2026-08-05 shares, plus long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end), minus cash 2026-06-30
FCF yield
-6.8%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$149.2M$74.9M$71.3M$65.2M
Gross profit$72.3M$54.2M$51.7M$49.7M
Operating income-$31.4M-$34.6M-$30.6M-$35.1M
Net income-$39.0M-$43.7M-$30.2M-$37.2M
EPS (diluted)-0.59-1.38-1.05-1.38
Operating cash flow-$20.4M-$31.0M-$32.0M-$30.7M
Cash$28.1M$18.5M$59.7M$70.3M
Long-term debt$65.8M$55.2M$59.3M$22.8M
SEC XBRL, fiscal years, as known on 2026-10-29

STIM Stock Sonar score 6/7 axes

Find similar shapesCompare

STIM ranks highest on growth (92nd percentile) and insider conviction (72nd), and lowest on financial health (28th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
37
Inputs
  • Return on equity-135.3% · 21 pct, sector of 183
  • Return on assets-22.9% · 45 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-21.8% · 45 pct, sector of 188
Financial health
28
Inputs
  • Debt to equity4.09x · 8 pct, sector of 159
  • Cash flow to debt-0.14x · 48 pct, sector of 150
Growth
92
Inputs
  • Revenue growth, YoY+99.2% · 92 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
72
Inputs
  • Net Form 4 buying (codes P and S), 180d$860K · 91 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
40
Inputs
  • Funds adding, latest quarter45 · 40 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
57
Inputs
  • Short interest, % of float+19.4% · 5 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+7.7% · 68 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

STIM filings, in plain words

Are Neuronetics insiders buying or selling STIM?

In the 180 days to 2026-10-29, Neuronetics insiders were net buyers, a net $860.0K across purchases and sales reported on Form 4, by 1 buyer.

Are there planned insider sales of STIM?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-29, covering $852.2K of stock; the latest, by MACAN WILLIAM ANDREW, was filed 2026-08-19.

Read the full summary

In the 180 days to 2026-10-29, Neuronetics insiders were net buyers of STIM, a net $860.0K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $860.0K, came from a holder of 10% or more rather than an officer or director. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-29, covering $852.2K of stock. The latest 5% ownership filing is a 13D by Chernett Jorey, filed 2026-03-31, for 14.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-29, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies